The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Hepatitis B Vaccine Market Research Report 2024
Synopsis
The hepatitis b vaccine is a vaccine against hepatitis b.That is, from hepatitis b virus carrier plasma isolation of hepatitis b surface antigen (HbsAg), after treatment and made.After second liver vaccine is inoculated, can stimulate immune system to produce protective antibody, this kind of antibody is in the humoral in the person, once second liver virus appears, antibody can act immediately, clear its, prevent infection, won't harm liver, make human body had the immunity that prevents second liver thereby.Therefore, hepatitis b vaccine has become an indispensable umbrella in life.Prevention generally lasts for at least 12 years, so there is no need for anti-hbs surveillance or enhanced immunity in the general population.However, anti-hbs surveillance can be carried out on high-risk groups, such as anti-hbs <10mIU/ml, which can be given enhanced immunity.
The global Recombinant Hepatitis B Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recombinant Hepatitis B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hepatitis B Vaccine.
Report Scope
The Recombinant Hepatitis B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Hepatitis B Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Hepatitis B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Hualan Biological Engineering
NCPC
China National Biotec Group
Dalian Hissen Bio-pharm
Beijing Tiantan Biological
Segment by Type
10mcg/ml
10mcg/0.5ml
Segment by Application
Newborn
Primary School Students
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Hepatitis B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Hepatitis B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The hepatitis b vaccine is a vaccine against hepatitis b.That is, from hepatitis b virus carrier plasma isolation of hepatitis b surface antigen (HbsAg), after treatment and made.After second liver vaccine is inoculated, can stimulate immune system to produce protective antibody, this kind of antibody is in the humoral in the person, once second liver virus appears, antibody can act immediately, clear its, prevent infection, won't harm liver, make human body had the immunity that prevents second liver thereby.Therefore, hepatitis b vaccine has become an indispensable umbrella in life.Prevention generally lasts for at least 12 years, so there is no need for anti-hbs surveillance or enhanced immunity in the general population.However, anti-hbs surveillance can be carried out on high-risk groups, such as anti-hbs <10mIU/ml, which can be given enhanced immunity.
The global Recombinant Hepatitis B Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recombinant Hepatitis B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hepatitis B Vaccine.
Report Scope
The Recombinant Hepatitis B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Hepatitis B Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Hepatitis B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Hualan Biological Engineering
NCPC
China National Biotec Group
Dalian Hissen Bio-pharm
Beijing Tiantan Biological
Segment by Type
10mcg/ml
10mcg/0.5ml
Segment by Application
Newborn
Primary School Students
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Hepatitis B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Hepatitis B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Hepatitis B Vaccine Market Overview
1.1 Product Overview and Scope of Recombinant Hepatitis B Vaccine
1.2 Recombinant Hepatitis B Vaccine Segment by Type
1.2.1 Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 10mcg/ml
1.2.3 10mcg/0.5ml
1.3 Recombinant Hepatitis B Vaccine Segment by Application
1.3.1 Global Recombinant Hepatitis B Vaccine Market Value by Application: (2024-2030)
1.3.2 Newborn
1.3.3 Primary School Students
1.3.4 Adult
1.4 Global Recombinant Hepatitis B Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Hepatitis B Vaccine Revenue 2019-2030
1.4.2 Global Recombinant Hepatitis B Vaccine Sales 2019-2030
1.4.3 Global Recombinant Hepatitis B Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Hepatitis B Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Hepatitis B Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Hepatitis B Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Hepatitis B Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Product Type & Application
2.7 Recombinant Hepatitis B Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant Hepatitis B Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Hepatitis B Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Hepatitis B Vaccine Retrospective Market Scenario by Region
3.1 Global Recombinant Hepatitis B Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Hepatitis B Vaccine Global Recombinant Hepatitis B Vaccine Sales by Region: 2019-2030
3.2.1 Global Recombinant Hepatitis B Vaccine Sales by Region: 2019-2024
3.2.2 Global Recombinant Hepatitis B Vaccine Sales by Region: 2025-2030
3.3 Global Recombinant Hepatitis B Vaccine Global Recombinant Hepatitis B Vaccine Revenue by Region: 2019-2030
3.3.1 Global Recombinant Hepatitis B Vaccine Revenue by Region: 2019-2024
3.3.2 Global Recombinant Hepatitis B Vaccine Revenue by Region: 2025-2030
3.4 North America Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Hepatitis B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Hepatitis B Vaccine Sales by Country (2019-2030)
3.4.3 North America Recombinant Hepatitis B Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Hepatitis B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Hepatitis B Vaccine Sales by Country (2019-2030)
3.5.3 Europe Recombinant Hepatitis B Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Hepatitis B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Hepatitis B Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Hepatitis B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Hepatitis B Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Hepatitis B Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Hepatitis B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Hepatitis B Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Hepatitis B Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Hepatitis B Vaccine Sales by Type (2019-2030)
4.1.1 Global Recombinant Hepatitis B Vaccine Sales by Type (2019-2024)
4.1.2 Global Recombinant Hepatitis B Vaccine Sales by Type (2025-2030)
4.1.3 Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Hepatitis B Vaccine Revenue by Type (2019-2030)
4.2.1 Global Recombinant Hepatitis B Vaccine Revenue by Type (2019-2024)
4.2.2 Global Recombinant Hepatitis B Vaccine Revenue by Type (2025-2030)
4.2.3 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Hepatitis B Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Hepatitis B Vaccine Sales by Application (2019-2030)
5.1.1 Global Recombinant Hepatitis B Vaccine Sales by Application (2019-2024)
5.1.2 Global Recombinant Hepatitis B Vaccine Sales by Application (2025-2030)
5.1.3 Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Hepatitis B Vaccine Revenue by Application (2019-2030)
5.2.1 Global Recombinant Hepatitis B Vaccine Revenue by Application (2019-2024)
5.2.2 Global Recombinant Hepatitis B Vaccine Revenue by Application (2025-2030)
5.2.3 Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Hepatitis B Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Recombinant Hepatitis B Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GlaxoSmithKline Plc
6.2.1 GlaxoSmithKline Plc Corporation Information
6.2.2 GlaxoSmithKline Plc Description and Business Overview
6.2.3 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Plc Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Corporation Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Inc. Recombinant Hepatitis B Vaccine Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Sanofi Pasteur
6.4.1 Sanofi Pasteur Corporation Information
6.4.2 Sanofi Pasteur Description and Business Overview
6.4.3 Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Pasteur Recombinant Hepatitis B Vaccine Product Portfolio
6.4.5 Sanofi Pasteur Recent Developments/Updates
6.5 CSL Limited
6.5.1 CSL Limited Corporation Information
6.5.2 CSL Limited Description and Business Overview
6.5.3 CSL Limited Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CSL Limited Recombinant Hepatitis B Vaccine Product Portfolio
6.5.5 CSL Limited Recent Developments/Updates
6.6 Emergent Biosolutions
6.6.1 Emergent Biosolutions Corporation Information
6.6.2 Emergent Biosolutions Description and Business Overview
6.6.3 Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Emergent Biosolutions Recombinant Hepatitis B Vaccine Product Portfolio
6.6.5 Emergent Biosolutions Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Serum Institute of India Recombinant Hepatitis B Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Johnson & Johnson
6.8.1 Johnson & Johnson Corporation Information
6.8.2 Johnson & Johnson Description and Business Overview
6.8.3 Johnson & Johnson Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Johnson & Johnson Recombinant Hepatitis B Vaccine Product Portfolio
6.8.5 Johnson & Johnson Recent Developments/Updates
6.9 Hualan Biological Engineering
6.9.1 Hualan Biological Engineering Corporation Information
6.9.2 Hualan Biological Engineering Description and Business Overview
6.9.3 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product Portfolio
6.9.5 Hualan Biological Engineering Recent Developments/Updates
6.10 NCPC
6.10.1 NCPC Corporation Information
6.10.2 NCPC Description and Business Overview
6.10.3 NCPC Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 NCPC Recombinant Hepatitis B Vaccine Product Portfolio
6.10.5 NCPC Recent Developments/Updates
6.11 China National Biotec Group
6.11.1 China National Biotec Group Corporation Information
6.11.2 China National Biotec Group Recombinant Hepatitis B Vaccine Description and Business Overview
6.11.3 China National Biotec Group Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 China National Biotec Group Recombinant Hepatitis B Vaccine Product Portfolio
6.11.5 China National Biotec Group Recent Developments/Updates
6.12 Dalian Hissen Bio-pharm
6.12.1 Dalian Hissen Bio-pharm Corporation Information
6.12.2 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Description and Business Overview
6.12.3 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product Portfolio
6.12.5 Dalian Hissen Bio-pharm Recent Developments/Updates
6.13 Beijing Tiantan Biological
6.13.1 Beijing Tiantan Biological Corporation Information
6.13.2 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Description and Business Overview
6.13.3 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product Portfolio
6.13.5 Beijing Tiantan Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Hepatitis B Vaccine Industry Chain Analysis
7.2 Recombinant Hepatitis B Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Hepatitis B Vaccine Production Mode & Process
7.4 Recombinant Hepatitis B Vaccine Sales and Marketing
7.4.1 Recombinant Hepatitis B Vaccine Sales Channels
7.4.2 Recombinant Hepatitis B Vaccine Distributors
7.5 Recombinant Hepatitis B Vaccine Customers
8 Recombinant Hepatitis B Vaccine Market Dynamics
8.1 Recombinant Hepatitis B Vaccine Industry Trends
8.2 Recombinant Hepatitis B Vaccine Market Drivers
8.3 Recombinant Hepatitis B Vaccine Market Challenges
8.4 Recombinant Hepatitis B Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Recombinant Hepatitis B Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Recombinant Hepatitis B Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Recombinant Hepatitis B Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Recombinant Hepatitis B Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Recombinant Hepatitis B Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Recombinant Hepatitis B Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Hepatitis B Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Hepatitis B Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hepatitis B Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Hepatitis B Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Recombinant Hepatitis B Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Recombinant Hepatitis B Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Recombinant Hepatitis B Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Recombinant Hepatitis B Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Recombinant Hepatitis B Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Recombinant Hepatitis B Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Recombinant Hepatitis B Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Recombinant Hepatitis B Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Recombinant Hepatitis B Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Recombinant Hepatitis B Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Recombinant Hepatitis B Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Recombinant Hepatitis B Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Recombinant Hepatitis B Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Recombinant Hepatitis B Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Recombinant Hepatitis B Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Recombinant Hepatitis B Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Recombinant Hepatitis B Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Recombinant Hepatitis B Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Recombinant Hepatitis B Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Recombinant Hepatitis B Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Recombinant Hepatitis B Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Recombinant Hepatitis B Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Recombinant Hepatitis B Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Recombinant Hepatitis B Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Recombinant Hepatitis B Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Recombinant Hepatitis B Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Recombinant Hepatitis B Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Recombinant Hepatitis B Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Recombinant Hepatitis B Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Recombinant Hepatitis B Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Recombinant Hepatitis B Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Recombinant Hepatitis B Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Recombinant Hepatitis B Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Merck Recombinant Hepatitis B Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. GlaxoSmithKline Plc Corporation Information
Table 76. GlaxoSmithKline Plc Description and Business Overview
Table 77. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. GlaxoSmithKline Plc Recombinant Hepatitis B Vaccine Product
Table 79. GlaxoSmithKline Plc Recent Developments/Updates
Table 80. Pfizer Inc. Corporation Information
Table 81. Pfizer Inc. Description and Business Overview
Table 82. Pfizer Inc. Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Pfizer Inc. Recombinant Hepatitis B Vaccine Product
Table 84. Pfizer Inc. Recent Developments/Updates
Table 85. Sanofi Pasteur Corporation Information
Table 86. Sanofi Pasteur Description and Business Overview
Table 87. Sanofi Pasteur Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi Pasteur Recombinant Hepatitis B Vaccine Product
Table 89. Sanofi Pasteur Recent Developments/Updates
Table 90. CSL Limited Corporation Information
Table 91. CSL Limited Description and Business Overview
Table 92. CSL Limited Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. CSL Limited Recombinant Hepatitis B Vaccine Product
Table 94. CSL Limited Recent Developments/Updates
Table 95. Emergent Biosolutions Corporation Information
Table 96. Emergent Biosolutions Description and Business Overview
Table 97. Emergent Biosolutions Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Emergent Biosolutions Recombinant Hepatitis B Vaccine Product
Table 99. Emergent Biosolutions Recent Developments/Updates
Table 100. Serum Institute of India Corporation Information
Table 101. Serum Institute of India Description and Business Overview
Table 102. Serum Institute of India Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Serum Institute of India Recombinant Hepatitis B Vaccine Product
Table 104. Serum Institute of India Recent Developments/Updates
Table 105. Johnson & Johnson Corporation Information
Table 106. Johnson & Johnson Description and Business Overview
Table 107. Johnson & Johnson Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Johnson & Johnson Recombinant Hepatitis B Vaccine Product
Table 109. Johnson & Johnson Recent Developments/Updates
Table 110. Hualan Biological Engineering Corporation Information
Table 111. Hualan Biological Engineering Description and Business Overview
Table 112. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Hualan Biological Engineering Recombinant Hepatitis B Vaccine Product
Table 114. Hualan Biological Engineering Recent Developments/Updates
Table 115. NCPC Corporation Information
Table 116. NCPC Description and Business Overview
Table 117. NCPC Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. NCPC Recombinant Hepatitis B Vaccine Product
Table 119. NCPC Recent Developments/Updates
Table 120. China National Biotec Group Corporation Information
Table 121. China National Biotec Group Description and Business Overview
Table 122. China National Biotec Group Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. China National Biotec Group Recombinant Hepatitis B Vaccine Product
Table 124. China National Biotec Group Recent Developments/Updates
Table 125. Dalian Hissen Bio-pharm Corporation Information
Table 126. Dalian Hissen Bio-pharm Description and Business Overview
Table 127. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Dalian Hissen Bio-pharm Recombinant Hepatitis B Vaccine Product
Table 129. Dalian Hissen Bio-pharm Recent Developments/Updates
Table 130. Beijing Tiantan Biological Corporation Information
Table 131. Beijing Tiantan Biological Description and Business Overview
Table 132. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Beijing Tiantan Biological Recombinant Hepatitis B Vaccine Product
Table 134. Beijing Tiantan Biological Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Recombinant Hepatitis B Vaccine Distributors List
Table 138. Recombinant Hepatitis B Vaccine Customers List
Table 139. Recombinant Hepatitis B Vaccine Market Trends
Table 140. Recombinant Hepatitis B Vaccine Market Drivers
Table 141. Recombinant Hepatitis B Vaccine Market Challenges
Table 142. Recombinant Hepatitis B Vaccine Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Hepatitis B Vaccine
Figure 2. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Recombinant Hepatitis B Vaccine Market Share by Type in 2023 & 2030
Figure 4. 10mcg/ml Product Picture
Figure 5. 10mcg/0.5ml Product Picture
Figure 6. Global Recombinant Hepatitis B Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Recombinant Hepatitis B Vaccine Market Share by Application in 2023 & 2030
Figure 8. Newborn
Figure 9. Primary School Students
Figure 10. Adult
Figure 11. Global Recombinant Hepatitis B Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Recombinant Hepatitis B Vaccine Market Size (2019-2030) & (US$ Million)
Figure 13. Global Recombinant Hepatitis B Vaccine Sales (2019-2030) & (K Units)
Figure 14. Global Recombinant Hepatitis B Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 15. Recombinant Hepatitis B Vaccine Report Years Considered
Figure 16. Recombinant Hepatitis B Vaccine Sales Share by Manufacturers in 2023
Figure 17. Global Recombinant Hepatitis B Vaccine Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Recombinant Hepatitis B Vaccine Players: Market Share by Revenue in 2023
Figure 19. Recombinant Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Recombinant Hepatitis B Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Recombinant Hepatitis B Vaccine Sales Market Share by Country (2019-2030)
Figure 22. North America Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Recombinant Hepatitis B Vaccine Sales Market Share by Country (2019-2030)
Figure 26. Europe Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2019-2030)
Figure 27. Germany Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Recombinant Hepatitis B Vaccine Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Recombinant Hepatitis B Vaccine Revenue Market Share by Region (2019-2030)
Figure 34. China Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Recombinant Hepatitis B Vaccine Sales Market Share by Country (2019-2030)
Figure 45. Latin America Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Recombinant Hepatitis B Vaccine Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Recombinant Hepatitis B Vaccine Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Recombinant Hepatitis B Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Recombinant Hepatitis B Vaccine by Type (2019-2030)
Figure 55. Global Revenue Market Share of Recombinant Hepatitis B Vaccine by Type (2019-2030)
Figure 56. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Recombinant Hepatitis B Vaccine by Application (2019-2030)
Figure 58. Global Revenue Market Share of Recombinant Hepatitis B Vaccine by Application (2019-2030)
Figure 59. Global Recombinant Hepatitis B Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 60. Recombinant Hepatitis B Vaccine Value Chain
Figure 61. Recombinant Hepatitis B Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
